Paracodin N (Dihydrocodeine Tartrate)

Paracodin N contains dihydrocodeine tartrate, an opioid that acts on the central nervous system to relieve pain.

• Acute postoperative pain: provides analgesia during the recovery period after surgery.
• Cancer‑related pain: helps control moderate to severe pain associated with malignant disease.
• Severe chronic non‑cancer pain: used when other analgesics are inadequate for persistent pain conditions.

• Dihydrocodeine tartrate binds to μ‑opioid receptors in the central nervous system, producing analgesia by inhibiting the transmission of nociceptive signals and altering pain perception. The drug also exerts mild activity at κ‑opioid receptors, contributing to its overall effect on pain modulation.

Paracodin N may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Constipation: reduced bowel motility leading to hard stools.
• Drowsiness or sedation: increased sleepiness or reduced alertness.
• Dizziness: sensation of light‑headedness or imbalance.
• Dry mouth: reduced salivation causing oral discomfort.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that may be life‑threatening.
• Severe hypotension: marked drop in blood pressure causing faintness.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Dependence or withdrawal: signs of physical dependence with abrupt discontinuation.
• Confusion or hallucinations: altered mental status in susceptible individuals.
• Urinary retention: difficulty initiating or maintaining urine flow.

When prescribing Paracodin N, clinicians should consider several safety aspects.

• Assess pain severity and prior opioid exposure: ensure appropriate indication before initiating therapy.
• Monitor for respiratory depression: especially in opioid‑naïve patients or those with pulmonary disease.
• Evaluate liver and kidney function: adjust use in patients with significant hepatic or renal impairment.
• Avoid concurrent CNS depressants: limit use with alcohol, benzodiazepines or other sedatives.
• Educate patients on dependence risk: discuss safe use, storage and disposal.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Paracodin N can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Other opioids or strong CNS depressants: may cause additive respiratory depression.
• Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): raise dihydrocodeine plasma levels.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may reduce conversion to active metabolites.
• Anticholinergic agents: can worsen constipation.
• Diuretics: may enhance hypotensive effects.
• Alcohol: potentiates sedation and respiratory depression.
• Antihistamines: increase drowsiness.